BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250928T093757EDT-0548hAulcF@132.216.98.100
DTSTAMP:20250928T133757Z
DESCRIPTION:Abstract: \n\nDefining efficient and robust chemical processes 
 to prepare an Active Pharmaceutical Ingredient (API) is foundational to ph
 armaceutical research. Molecules that are invented to improve the course o
 f human health must be synthesized by routes that don’t offset those advan
 tages for reasons of excessive waste generation\, high manufacturing cost 
 or unreliable supply. The role of the industrial process chemist is\, in p
 art\, to ensure the positive benefits of these medicines to society as who
 le are maintained when they are introduced into the marketplace and synthe
 sized time and again over decades of use. In this seminar\, process develo
 pment and the innovations in reaction and process design that underpinned 
 the commercial route for several API’s will be described.\n\n \n\nBio:\n\n
 Don Gauthier received his B.S. in chemistry from the University of Massach
 usetts\, Dartmouth and completed his doctoral thesis at the University of 
 California\, Irvine under the guidance of Professor Kenneth J. Shea. After
  a postdoctoral appointment with Professor Erick Carreira at the Californi
 a Institute of Technology Don began his industrial career with Merck in 19
 97. During Don’s 20+ years in Process Research & Development\, he has assu
 med various roles of increasing responsibility. Don’s early years in Merck
  Process were spent delivering on pipeline objectives for several early an
 d late phase clinical candidates. During a brief stint in the Merck Labele
 d Compound Synthesis group\, Don pioneered several novel methods to stream
 line and expedite the production of 13C and 14C labeled clinical candidate
 s. More recently\, Don served as a mentor and group leader responsible for
  designing innovative and efficient manufacturing routes to Merck products
 \, including several late stage clinical candidates and approved products 
 such as Sugammadex ®\, Ceftolozane® (antibiotic component of Zerbaxa®)\, G
 efapixant\, Islatravir\, Pifeltro® and Delstrigo®. Don and his Merck colle
 agues recently earned consecutive Green Chemistry Challenge awards\, first
  in 2018 for the manufacturing route to Doravirine®\, and in 2019 for the 
 manufacturing route to Ceftolozane®. Don also received the 2021 Edison Pat
 ent Award for his work on Doravirine. He is currently a Senior Principal S
 cientist in the Process Chemistry group in Rahway\, NJ.\n\n \n
DTSTART:20220426T170000Z
DTEND:20220426T183000Z
LOCATION:Room 10\, Maass Chemistry Building\, CA\, QC\, Montreal\, H3A 0B8\
 , 801 rue Sherbrooke Ouest
SUMMARY:Chemical Society Seminar: Don Gauthier - Green and Sustainable Chem
 istry for Manufacturing on Scale
URL:/chemistry/channels/event/chemical-society-seminar
 -don-gauthier-green-and-sustainable-chemistry-manufacturing-scale-338329
END:VEVENT
END:VCALENDAR